Armata Pharmaceuticals, Inc. (ARMP)
USD 1.13
(-9.6%)
USD 1.13
(-9.6%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 106.84 Million USD | 214.6% |
| 2022 | 33.96 Million USD | 22.61% |
| 2021 | 27.7 Million USD | 691.23% |
| 2020 | 3.5 Million USD | 210.44% |
| 2019 | -3.17 Million USD | 61.14% |
| 2018 | -8.15 Million USD | -58.94% |
| 2017 | -5.13 Million USD | -4.56% |
| 2016 | -4.9 Million USD | 47.62% |
| 2015 | -9.37 Million USD | -42.38% |
| 2014 | -6.58 Million USD | 67.67% |
| 2013 | -20.35 Million USD | -830.62% |
| 2012 | 2.78 Million USD | 0.0% |
| 2008 | -5.21 Million USD | 67.61% |
| 2007 | -16.1 Million USD | -257.36% |
| 2006 | -4.5 Million USD | 22.16% |
| 2005 | -5.79 Million USD | 74.43% |
| 2004 | -22.64 Million USD | -165.16% |
| 2003 | -8.54 Million USD | -192.97% |
| 2002 | 9.18 Million USD | 222.89% |
| 2001 | -7.47 Million USD | 78.85% |
| 2000 | -35.34 Million USD | -4318.24% |
| 1999 | -800 Thousand USD | -500.0% |
| 1998 | 200 Thousand USD | -86.67% |
| 1997 | 1.5 Million USD | 1600.0% |
| 1996 | -100 Thousand USD | -109.09% |
| 1995 | 1.1 Million USD | 83.33% |
| 1994 | 600 Thousand USD | 0.0% |
| 1993 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 119.73 Million USD | -7.93% |
| 2024 Q1 | 130.04 Million USD | 21.71% |
| 2023 Q4 | 106.84 Million USD | 19.16% |
| 2023 FY | 106.84 Million USD | 214.6% |
| 2023 Q2 | 13.89 Million USD | -73.39% |
| 2023 Q3 | 89.67 Million USD | 545.3% |
| 2023 Q1 | 52.22 Million USD | 53.77% |
| 2022 Q4 | 33.96 Million USD | 141.49% |
| 2022 Q2 | 1.96 Million USD | 124.62% |
| 2022 FY | 33.96 Million USD | 22.61% |
| 2022 Q1 | -7.96 Million USD | -128.75% |
| 2022 Q3 | 14.06 Million USD | 617.19% |
| 2021 Q3 | 238 Thousand USD | 105.33% |
| 2021 FY | 27.7 Million USD | 691.23% |
| 2021 Q2 | -4.46 Million USD | 52.27% |
| 2021 Q1 | -9.34 Million USD | -367.01% |
| 2021 Q4 | 27.7 Million USD | 11539.08% |
| 2020 Q4 | 3.5 Million USD | 222.84% |
| 2020 Q2 | -7.12 Million USD | 67.11% |
| 2020 Q3 | -2.85 Million USD | 59.99% |
| 2020 Q1 | -21.65 Million USD | -583.19% |
| 2020 FY | 3.5 Million USD | 210.44% |
| 2019 Q4 | -3.17 Million USD | 42.77% |
| 2019 Q3 | -5.53 Million USD | 41.79% |
| 2019 Q2 | -9.51 Million USD | -71.91% |
| 2019 Q1 | -5.53 Million USD | 32.14% |
| 2019 FY | -3.17 Million USD | 61.14% |
| 2018 Q4 | -8.15 Million USD | -81.31% |
| 2018 Q1 | -8.2 Million USD | -59.9% |
| 2018 Q2 | -5.79 Million USD | 29.34% |
| 2018 FY | -8.15 Million USD | -58.94% |
| 2018 Q3 | -4.49 Million USD | 22.4% |
| 2017 Q3 | -7.42 Million USD | 11.2% |
| 2017 Q2 | -8.35 Million USD | -420.95% |
| 2017 FY | -5.13 Million USD | -4.56% |
| 2017 Q4 | -5.13 Million USD | 30.84% |
| 2017 Q1 | -1.6 Million USD | 67.32% |
| 2016 Q1 | -6.17 Million USD | 34.12% |
| 2016 Q2 | -7.14 Million USD | -15.73% |
| 2016 Q3 | -3.96 Million USD | 44.47% |
| 2016 Q4 | -4.9 Million USD | -23.72% |
| 2016 FY | -4.9 Million USD | 47.62% |
| 2015 Q3 | -11.73 Million USD | 18.21% |
| 2015 FY | -9.37 Million USD | -42.38% |
| 2015 Q4 | -9.37 Million USD | 20.17% |
| 2015 Q2 | -14.35 Million USD | 13.68% |
| 2015 Q1 | -16.62 Million USD | -152.62% |
| 2014 Q1 | -16.43 Million USD | 19.26% |
| 2014 Q2 | -12.55 Million USD | 23.64% |
| 2014 Q3 | -9.78 Million USD | 22.02% |
| 2014 FY | -6.58 Million USD | 67.67% |
| 2014 Q4 | -6.58 Million USD | 32.75% |
| 2013 Q4 | -20.35 Million USD | 0.0% |
| 2013 FY | -20.35 Million USD | -830.62% |
| 2012 FY | 2.78 Million USD | 0.0% |
| 2009 Q3 | -3.97 Million USD | -60.96% |
| 2009 Q2 | -2.46 Million USD | 36.95% |
| 2009 Q1 | -3.91 Million USD | 24.92% |
| 2008 FY | -5.21 Million USD | 67.61% |
| 2008 Q1 | -12.52 Million USD | 22.22% |
| 2008 Q2 | -12.36 Million USD | 1.29% |
| 2008 Q3 | -9.18 Million USD | 25.74% |
| 2008 Q4 | -5.21 Million USD | 43.2% |
| 2007 Q1 | -9.57 Million USD | -112.36% |
| 2007 FY | -16.1 Million USD | -257.36% |
| 2007 Q2 | -24.36 Million USD | -154.59% |
| 2007 Q4 | -16.1 Million USD | 19.58% |
| 2007 Q3 | -20.02 Million USD | 17.81% |
| 2006 FY | -4.5 Million USD | 22.16% |
| 2006 Q1 | -7.72 Million USD | -33.35% |
| 2006 Q2 | -3.95 Million USD | 48.84% |
| 2006 Q4 | -4.5 Million USD | -316.16% |
| 2006 Q3 | -1.08 Million USD | 72.58% |
| 2005 Q4 | -5.79 Million USD | 33.95% |
| 2005 FY | -5.79 Million USD | 74.43% |
| 2005 Q3 | -8.76 Million USD | 40.23% |
| 2005 Q1 | -19.31 Million USD | 14.71% |
| 2005 Q2 | -14.66 Million USD | 24.07% |
| 2004 Q1 | -28.8 Million USD | -237.28% |
| 2004 Q2 | -24.99 Million USD | 13.22% |
| 2004 Q3 | -19.75 Million USD | 20.97% |
| 2004 Q4 | -22.64 Million USD | -14.64% |
| 2004 FY | -22.64 Million USD | -165.16% |
| 2003 Q1 | 9.87 Million USD | 7.52% |
| 2003 Q4 | -8.54 Million USD | 36.49% |
| 2003 Q2 | -2.65 Million USD | -126.83% |
| 2003 Q3 | -13.44 Million USD | -407.43% |
| 2003 FY | -8.54 Million USD | -192.97% |
| 2002 Q1 | 1.06 Million USD | 114.25% |
| 2002 FY | 9.18 Million USD | 222.89% |
| 2002 Q2 | 5.85 Million USD | 449.3% |
| 2002 Q4 | 9.18 Million USD | 41.85% |
| 2002 Q3 | 6.47 Million USD | 10.7% |
| 2001 Q1 | -30.89 Million USD | 12.59% |
| 2001 Q4 | -7.47 Million USD | 49.73% |
| 2001 Q3 | -14.87 Million USD | 31.64% |
| 2001 Q2 | -21.75 Million USD | 29.59% |
| 2001 FY | -7.47 Million USD | 78.85% |
| 2000 Q2 | -24.57 Million USD | 5.79% |
| 2000 Q3 | -35.2 Million USD | -43.23% |
| 2000 Q4 | -35.34 Million USD | -0.4% |
| 2000 FY | -35.34 Million USD | -4318.24% |
| 2000 Q1 | -26.08 Million USD | -3161.06% |
| 1999 Q2 | 700 Thousand USD | -58.82% |
| 1999 FY | -800 Thousand USD | -500.0% |
| 1999 Q4 | -800 Thousand USD | 70.37% |
| 1999 Q1 | 1.7 Million USD | 750.0% |
| 1999 Q3 | -2.7 Million USD | -485.71% |
| 1998 Q1 | 2.2 Million USD | 46.67% |
| 1998 Q2 | 900 Thousand USD | -59.09% |
| 1998 Q3 | 600 Thousand USD | -33.33% |
| 1998 Q4 | 200 Thousand USD | -66.67% |
| 1998 FY | 200 Thousand USD | -86.67% |
| 1997 FY | 1.5 Million USD | 1600.0% |
| 1997 Q1 | 2.4 Million USD | 2500.0% |
| 1997 Q2 | 2.9 Million USD | 20.83% |
| 1997 Q3 | -400 Thousand USD | -113.79% |
| 1997 Q4 | 1.5 Million USD | 475.0% |
| 1996 Q1 | 2.1 Million USD | 90.91% |
| 1996 FY | -100 Thousand USD | -109.09% |
| 1996 Q4 | -100 Thousand USD | -109.09% |
| 1996 Q2 | -3.7 Million USD | -276.19% |
| 1996 Q3 | 1.1 Million USD | 129.73% |
| 1995 Q4 | 1.1 Million USD | 466.67% |
| 1995 FY | 1.1 Million USD | 83.33% |
| 1995 Q3 | -300 Thousand USD | -112.0% |
| 1995 Q1 | 2.4 Million USD | 300.0% |
| 1995 Q2 | 2.5 Million USD | 4.17% |
| 1994 FY | 600 Thousand USD | 0.0% |
| 1994 Q4 | 600 Thousand USD | 140.0% |
| 1994 Q2 | -3.9 Million USD | 0.0% |
| 1994 Q3 | -1.5 Million USD | 61.54% |
| 1993 FY | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 2261.165% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 2900.734% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 243.297% |
| Azitra, Inc. | -910.04 Thousand USD | 11840.997% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 2621.189% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | -9014.437% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | -1959.919% |
| CEL-SCI Corporation | 9.42 Million USD | -1033.544% |
| iBio, Inc. | -9.75 Million USD | 1195.877% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 428.864% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 1594.232% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | 8440.984% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -24269.817% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | 27496.923% |
| NanoViricides, Inc. | -4.79 Million USD | 2327.031% |
| Oragenics, Inc. | -3.17 Million USD | 3469.751% |
| BiomX Inc. | -772 Thousand USD | 13940.415% |
| BiomX Inc. | -772 Thousand USD | 13940.415% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | -3936.57% |
| Palatin Technologies, Inc. | -8.93 Million USD | 1295.561% |
| Scorpius Holdings, Inc. | 13.85 Million USD | -671.069% |
| Theriva Biologics, Inc. | -21.02 Million USD | 608.243% |